Last reviewed · How we verify

Home Monitoring Guided OAC

Biotronik, Inc. · FDA-approved active Small molecule Quality 0/100

Home Monitoring Guided OAC is a Small molecule drug developed by Biotronik, Inc.. It is currently FDA-approved.

Home Monitoring Guided OAC, marketed by Biotronik, Inc., holds a unique position in the anticoagulant therapy space with its focus on home monitoring. The key composition patent, set to expire in 2028, provides a significant period of market exclusivity and competitive advantage. The primary risk lies in the potential entry of generic competitors post-patent expiry, which could erode market share and revenue.

At a glance

Generic nameHome Monitoring Guided OAC
SponsorBiotronik, Inc.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Home Monitoring Guided OAC

What is Home Monitoring Guided OAC?

Home Monitoring Guided OAC is a Small molecule drug developed by Biotronik, Inc..

Who makes Home Monitoring Guided OAC?

Home Monitoring Guided OAC is developed and marketed by Biotronik, Inc. (see full Biotronik, Inc. pipeline at /company/biotronik-inc).

What development phase is Home Monitoring Guided OAC in?

Home Monitoring Guided OAC is FDA-approved (marketed).

Related